Endocrine Abstracts

The aim: To evaluate the efficiency and safety of using closed loop systems in patients with type 1 DM living in Russia.

Results: 88 respondents (or those legal representatives) with type 1 DM in insulin therapy by closed loop systems, members of Russian-speaking community, were included to the study. 90% of respondents living in Russia. All respondents using do-it-yourself artificial pancreas systems (DIYAPS): Loop (19.3%), Open APS (30.7%) and Android APS (50%). Hlycated haemoglobin was normal in 90% of cases of using DIYAPS. 89% of respondents notice improvement of glycemic control. Among the advantages of closed loop therapy, respondents noted an increase time-in-range (78% of respondents), a decrease in the frequency of mild hypoglycemia (61% of respondents), a decrease in the frequency of severe hypoglycemia (59% of respondents), and improved glycemic control at night (86% of respondents) .

Conclusions: The use of pump insulin therapy using closed loop systems leads to a decrease in the level of glycated hemoglobin by 0.5% (P = 0.01) compared with the use of standard pump insulin therapy. The majority (78%) of type 1 DM respondents receiving closed-loop pump insulin therapy noted an increase in the time-in-range compared to standard pump insulin therapy. The use of closed-loop systems is associated with a decrease in the frequency ofmild (in 61% of respondents) and severe hypoglycemic conditions (in 59% of respondents) compared to standard pump insulin therapy in respondents with type 1 DM.